JP2023182691A5 - - Google Patents
Info
- Publication number
- JP2023182691A5 JP2023182691A5 JP2023169177A JP2023169177A JP2023182691A5 JP 2023182691 A5 JP2023182691 A5 JP 2023182691A5 JP 2023169177 A JP2023169177 A JP 2023169177A JP 2023169177 A JP2023169177 A JP 2023169177A JP 2023182691 A5 JP2023182691 A5 JP 2023182691A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- seq
- acid sequence
- set forth
- sequence set
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762548632P | 2017-08-22 | 2017-08-22 | |
| US62/548,632 | 2017-08-22 | ||
| PCT/US2018/047286 WO2019040471A1 (en) | 2017-08-22 | 2018-08-21 | METHODS OF TREATING UREA CYCLE DISORDERS BY INTERFERING WITH GLUCAGON RECEPTOR SIGNALING |
| JP2020511375A JP7781519B2 (ja) | 2017-08-22 | 2018-08-21 | グルカゴン受容体シグナル伝達に干渉することによって尿素サイクル異常症を治療する方法 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020511375A Division JP7781519B2 (ja) | 2017-08-22 | 2018-08-21 | グルカゴン受容体シグナル伝達に干渉することによって尿素サイクル異常症を治療する方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023182691A JP2023182691A (ja) | 2023-12-26 |
| JP2023182691A5 true JP2023182691A5 (cg-RX-API-DMAC7.html) | 2026-01-29 |
Family
ID=63638351
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020511375A Active JP7781519B2 (ja) | 2017-08-22 | 2018-08-21 | グルカゴン受容体シグナル伝達に干渉することによって尿素サイクル異常症を治療する方法 |
| JP2023169177A Pending JP2023182691A (ja) | 2017-08-22 | 2023-09-29 | グルカゴン受容体シグナル伝達に干渉することによって尿素サイクル異常症を治療する方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020511375A Active JP7781519B2 (ja) | 2017-08-22 | 2018-08-21 | グルカゴン受容体シグナル伝達に干渉することによって尿素サイクル異常症を治療する方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US12139546B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3672620A1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7781519B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3071387A1 (cg-RX-API-DMAC7.html) |
| MX (2) | MX2020002057A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2019040471A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020210642A1 (en) * | 2019-04-10 | 2020-10-15 | Camp4 Therapeutics Corporation | Methods and compositions for treating urea cycle disorders |
| CA3205005A1 (en) * | 2020-12-16 | 2022-06-23 | Rush University Medical Center | Administration of glycerol tribenzoate and glycerol phenylbutyrate for treatment of neurodegenerative and urea cycle disorders |
| KR20240126870A (ko) | 2021-12-22 | 2024-08-21 | 캠프4 테라퓨틱스 코포레이션 | 조절 rna들을 표적으로 하는 안티센스 올리고뉴클레오티드를 사용한 유전자 전사의 조절 |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5836308B2 (ja) | 1977-02-10 | 1983-08-08 | 大塚製薬株式会社 | 抗体の製造方法 |
| US4206199A (en) | 1977-07-22 | 1980-06-03 | Takeda Chemical Industries, Ltd. | Novel glucagon fragment and its derivatives |
| JPS56163456A (en) | 1980-05-21 | 1981-12-16 | Otsuka Pharmaceut Co Ltd | Preparation of antigen |
| US4423034A (en) | 1980-10-16 | 1983-12-27 | Toyo Jozo Kabushiki Kaisha | Process for the preparation of antibodies |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| HU219674B (hu) | 1992-08-28 | 2001-06-28 | Novo Nordisk A/S | Glukagon-receptort kódoló DNS-molekulák, glukagon-receptor peptidek, glukagon-receptort blokkoló monoklonális ellenanyagok, és eljárások előállításukra |
| JP2729159B2 (ja) | 1994-10-31 | 1998-03-18 | 日清製粉株式会社 | ヒトグリセンチンのモノクローナル抗体、この抗体を産生するハイブリドーマおよびそれを用いるヒトグリセンチンの定量法 |
| US20040101920A1 (en) | 2002-11-01 | 2004-05-27 | Czeslaw Radziejewski | Modification assisted profiling (MAP) methodology |
| CA2547785A1 (en) | 2003-12-19 | 2005-07-21 | Merck & Co., Inc. | Cyclic guanidines, compositions containing such compounds and methods of use |
| NZ551405A (en) | 2004-06-04 | 2009-06-26 | Merck & Co Inc | Pyrazole derivatives, compositions containing such compounds and methods of use |
| DE102004028862A1 (de) | 2004-06-15 | 2005-12-29 | Merck Patent Gmbh | 3-Aminoindazole |
| CN1980665A (zh) | 2004-07-07 | 2007-06-13 | 默克公司 | 吡唑酰胺衍生物，包含这些化合物的组合物和使用方法 |
| WO2006014618A2 (en) | 2004-07-22 | 2006-02-09 | Merck & Co., Inc. | Substituted pyrazoles, compositions containing such compounds and methods of use |
| ES2332470T3 (es) | 2005-02-11 | 2010-02-05 | Eli Lilly And Company | Derivados de tiofeno sustituidos como antagonistas del receptor de glucagon, preparacion y usos terapeuticos. |
| US8318760B2 (en) | 2005-03-21 | 2012-11-27 | Merck Sharp & Dohme Corp. | Substituted aryl and heteroaryl derivatives, compositions containing such compounds and methods of use |
| JP2008534593A (ja) | 2005-03-30 | 2008-08-28 | メルク エンド カムパニー インコーポレーテッド | グルカゴン受容体アンタゴニスト化合物、そのような化合物を含む組成物、及びその使用方法 |
| AR056574A1 (es) | 2005-10-19 | 2007-10-10 | Merck & Co Inc | Derivados de pirazol, composiciones que contienen dichos compuestos y procedimientos de uso |
| MX2008013459A (es) | 2006-04-20 | 2008-10-30 | Amgen Inc | Composiciones de anticuerpos glucagon/compuesto de peptido 1 similar al glucagon (glp-1). |
| CL2007002668A1 (es) | 2006-09-20 | 2008-05-09 | Amgen Inc | Proteina de union a antigeno que se une al receptor de glucagon humano; acido nucleico que la codifica; metodo de produccion; composicion farmaceutica que la comprende; y su uso para tratar o prevenir la diabetes tipo 2. |
| TW200821284A (en) | 2006-10-03 | 2008-05-16 | Merck & Co Inc | Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use |
| KR20200123866A (ko) | 2007-02-09 | 2020-10-30 | 메타베이시스 테라퓨틱스, 인크. | 글루카곤 수용체의 길항제 |
| AR070844A1 (es) | 2008-03-27 | 2010-05-05 | Lilly Co Eli | Fragmento fab o anticuerpo monoclonal humanizado que comprende el fragmento fab, y su uso para la manufactura de un medicamento antagonista del polipeptido del receptor de glucagon para el tratamiento o prevencion de diabetes de tipo 1 o 2 |
| WO2009140342A1 (en) | 2008-05-16 | 2009-11-19 | Schering Corporation | Glucagon receptor antagonists, compositions, and methods for their use |
| EP2346830B1 (en) | 2008-09-15 | 2015-05-13 | Merck Sharp & Dohme Corp. | Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use |
| US8445538B2 (en) | 2008-12-19 | 2013-05-21 | Merck Sharp & Dohme Corp. | Glucagon receptor antagonist compounds |
| WO2010088061A1 (en) | 2009-01-28 | 2010-08-05 | Merck Sharp & Dohme Corp. | Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use |
| US8324384B2 (en) | 2009-02-12 | 2012-12-04 | Merck Sharp & Dohme Corp. | Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use |
| WO2010098948A1 (en) | 2009-02-13 | 2010-09-02 | Merck Sharp & Dohme Corp. | Glucagon receptor antagonist compounds, compositions containin such compounds and methods of use |
| US8318667B2 (en) | 2009-02-25 | 2012-11-27 | Merck Sharp & Dohme Corp. | Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use |
| JP2012188352A (ja) | 2009-07-13 | 2012-10-04 | Dainippon Sumitomo Pharma Co Ltd | ３−（４−置換アルキル−フェニル）−２−フランカルボン酸誘導体およびその薬学的に許容される塩 |
| FR2959129B1 (fr) * | 2010-04-21 | 2013-02-01 | Lucane Pharma | Particules comprenant du 4-phenylbutyrate de sodium, procede de preparation et utilisations |
| JO3756B1 (ar) | 2010-11-23 | 2021-01-31 | Regeneron Pharma | اجسام مضادة بشرية لمستقبلات الجلوكاجون |
| EP3263102A1 (en) * | 2011-09-30 | 2018-01-03 | Horizon Therapeutics, LLC | Methods of therapeutic monitoring of nitrogen scavenging drugs |
| EP2785740A1 (en) | 2011-12-02 | 2014-10-08 | Eli Lilly and Company | Anti-glucagon antibodies and uses thereof |
| CN107001461A (zh) | 2014-09-16 | 2017-08-01 | 瑞泽恩制药公司 | 抗胰高血糖素抗体及其使用方法 |
-
2018
- 2018-08-21 CA CA3071387A patent/CA3071387A1/en active Pending
- 2018-08-21 US US16/640,907 patent/US12139546B2/en active Active
- 2018-08-21 MX MX2020002057A patent/MX2020002057A/es unknown
- 2018-08-21 WO PCT/US2018/047286 patent/WO2019040471A1/en not_active Ceased
- 2018-08-21 JP JP2020511375A patent/JP7781519B2/ja active Active
- 2018-08-21 EP EP18772997.5A patent/EP3672620A1/en active Pending
-
2020
- 2020-02-21 MX MX2024011106A patent/MX2024011106A/es unknown
-
2023
- 2023-09-29 JP JP2023169177A patent/JP2023182691A/ja active Pending
-
2024
- 2024-10-03 US US18/906,101 patent/US20250101119A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023182691A5 (cg-RX-API-DMAC7.html) | ||
| JP2024016177A5 (cg-RX-API-DMAC7.html) | ||
| JP7551822B2 (ja) | 治療用抗体製剤 | |
| RU2006120950A (ru) | Антитело к cd40: препарат и способы | |
| WO2021083271A1 (zh) | 含有抗pd-l1抗体的稳定制剂 | |
| KR102039198B1 (ko) | 악액질 치료법 | |
| JP2024531151A5 (cg-RX-API-DMAC7.html) | ||
| CN114762678B (zh) | 抗tigit抗体药物组合物及其用途 | |
| JP7398958B2 (ja) | 安定的抗ｏｓｍｒ抗体製剤 | |
| JP2022121658A (ja) | アミロイドーシスを処置するための組成物 | |
| TWI860741B (zh) | Pvrig/tigit雙特異性抗體藥物組合物及其用途 | |
| JP2020531532A5 (cg-RX-API-DMAC7.html) | ||
| HRP20160302T1 (hr) | Monoklonska protutijela protiv feroportina 1 i njihova upotreba | |
| JP7781519B2 (ja) | グルカゴン受容体シグナル伝達に干渉することによって尿素サイクル異常症を治療する方法 | |
| US20190322734A1 (en) | Treatment paradigm | |
| JP2021533142A5 (cg-RX-API-DMAC7.html) | ||
| EP3703819A1 (en) | Method of treating tendinopathy using interleukin-17 (il-17) antagonists | |
| KR20250079929A (ko) | 항-FcRN 항체를 이용한 그레이브스병의 치료 방법 | |
| KR20250011948A (ko) | 인터류킨-17(il-17) 길항제를 사용하여 건병증을 선택적으로 치료하는 방법 | |
| RU2824627C2 (ru) | Фармацевтическая композиция анти-cd20 антитела и ее применение | |
| US20240238272A1 (en) | Treatment of antiphospholipid syndrome using s-hydroxychloroquine | |
| US20250340643A1 (en) | Anti-CTLA Antibody Compositions and Related Methods | |
| RU2025126086A (ru) | Композиции, содержащие биспецифическое антитело к gprc5d/cd3 | |
| RU2025129547A (ru) | Способы применения мультиспецифических связывающих белков | |
| HK40102408B (zh) | 含抗lag-3抗体的药物组合物及其用途 |